期刊文献+

MMP-2,-9及其抑制物TIMP-1在多囊卵巢综合征患者黄素化颗粒细胞上的表达 被引量:1

Matrix metalloproteinases 2 and 9 and their tissue inhibitors in ovarian luteinized granulosa cells of patients with polycystic ovarian syndrome
暂未订购
导出
摘要 目的分析多囊卵巢综合征(PCOS)患者黄素化颗粒细胞上基质金属蛋白酶-2,-9(MMP-2,-9)及其组织抑制物TIMP-1的蛋白及mRNA在不同培养时间的表达水平,了解与细胞外基质合成、降解相关的MMPs/TIMPs系统参与PCOS的病理生理机制。方法收集2011年9月到2012年1月行体外受精(IVF)或卵胞浆内单精子注射(ICSI)治疗的PCOS患者30例,对照组为同期行IVF或ICSI治疗的不孕症患者30例。密度梯度法获得卵巢黄素化颗粒细胞,细胞贴壁培养,分别在培养24、48和72h收集颗粒细胞。采用Western blotting方法检测颗粒细胞中MMP-2、MMP-9和TIMP-1的蛋白表达;RT-PCR检测颗粒细胞中MMP-2、MMP-9和TIMP-1mRNA的表达。结果 (1)PCOS组黄素化颗粒细胞MMP-2,-9蛋白表达在各培养时间点(24、48、72h)均显著高于对照组(P均<0.05);且MMP-2蛋白表达水平在48、72h相对于24h的比值,以及MMP-9蛋白表达水平在72h相对于24h的比值,PCOS组均显著高于对照组(P均<0.01)。(2)PCOS组MMP-2mRNA在24、48、72h的表达,MMP-9mRNA在48、72h的表达均高于对照组,差异有统计学意义(P均<0.05);MMP-2,-9mRNA表达水平在48、72h相对于24h的比值,PCOS组高于对照组,差异均有统计学意义(P均<0.05)。(3)PCOS组TIMP-1蛋白及mRNA表达在24、48、72h与对照组比较无统计学差异(P>0.05)。结论 PCOS患者黄素化颗粒细胞中MMP-2和MMP-9的表达升高,其MMPs/TIMPs的平衡状态向蛋白酶的活性增强方向移动,可能与PCOS患者黄体功能不足有关。 Objective:To evaluate the protein and mRNA expression of matrix metalloproteinase-2,-9(MMP-2,-9)and matrix metalloproteinase inhibitor-1(TIMP-1)in luteinized granulosa cells of polycystic ovary syndrome(PCOS)patients,and further explore the relationship between MMPs/TIMPs system and pathophysiology of PCOS.Methods:Ovarian luteinized granulosa cells were isolated from 30 patients with PCOS and 30 control women with regular menses cycle.They were all from in vitro fertilization program.The cultured granulosa cells were collected in 24,48 and 72hours after cell adhesion.The expressions of MMP-2,MMP-9 and TIMP-1protein of luteinized granulosa cells were detected by Western blot.The expressions of MMP-2,MMP-9and TIMP-1mRNA of luteinized granulosa cells were assessed by reverse transcription polymerase chain reaction(RT-PCR).Results:MMP-2,-9protein expressions of ovarian luteinized granulosa cells from the patients with PCOS in 24,48 and 72hours after cultured were significantly higher than those in control group(P〈0.05).Compared with that in control group,the ratio of MMP-2protein expression between 48 or 72hours and 24 hours,and the ratio of MMP-9protein expression between 72 and 24hours were significantly higher in the patients with PCOS(P〈0.01).MMP-2mRNA expression in 24,48 and 72hours and MMP-9mRNA expression in 48 and 72hours after cultured in the patients with PCOS were significantly higher than those in control group(P〈0.05).The ratio of MMP-2,-9mRNA expressions between 48 or 72hours and 24 hours in the patients with PCOS were significantly higher than those in control group(P〈0.05).No statistic difference was found in the expression of TIMP-1protein and mRNA in 24,48 and 72hours after cultured between patients with PCOS and controls(P〉0.05).Conclusions:The expressions of MMP-2 and MMP-9in cultured luteinized granulosa cells of patients with PCOS are higher than those in the control group,while the expression of TIMP-1has no significant difference.The shift to increased protease activity from MMPs/TIMPs equilibrium state may be associated with luteal defect in patients with PCOS.
出处 《生殖医学杂志》 CAS 2014年第6期464-469,共6页 Journal of Reproductive Medicine
基金 河北省计生委指令计划(2010-A12) 中国博士后科学基金(2011M500538)
关键词 多囊卵巢综合征 基质金属蛋白酶-2 基质金属蛋白酶-9 基质金属蛋白酶抑制剂-1 粒层细胞 Polycystic ovary syndrome Matrix metalloproteinase-2 Matrix metalloproteinase-9 Matrix metalloproteinase inhibitor-1 Granulosa cell
  • 相关文献

参考文献2

二级参考文献61

  • 1[1]Hazzard,T.M.,Stouffer,R.L.,Angiogenesis in ovarian follicular and luteal development,Baillieres Best Pract.Res.Clin.Obstet.Gynaecol.,2000,14:883-900.
  • 2[2]Reynolds,L.P.,Grazul-Bilska,A.T.,Redmer,D.A.,Angiogenesis in the corpus luteum,Endocrine,2000,12:1-9.
  • 3[3]Reynolds,L.P.,Redmer,D.A.,Growth and development of corpus luteum,J.Reprod.Fertil.Suppl.,1999,54:181-191.
  • 4[4]Rothchild,I.,The regulation of the mammalian corpus luteum,Recent Prog.Horm.Res.,1981,37:183-298.
  • 5[5]Niswender,G.D.,Nett,T.M.,The corpus luteum and its control in infraprimate species,in The Physiology of Reproduction (eds.Knobil,E.,Neill,J.),New York:Raven Press,2000,781-816.
  • 6[6]Liu,K.,Brandstrom,A.,Liu,Y.X.et al.,Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 during corpus luteum formation and luteolysis in the adult pseudopregnant rats,Endocrinology,1996,137:2126-2132.
  • 7[7]Liu,K.,Liu,Y.X.,Hu,Z.Y.et al.,Temporal expression of urokinase type plasminogen activator,plasminogen activator inhibitor type-1 in rhesus monkey corpus luteum during the luteal maintenance and regression,Mol.Cell Endocrinol.,1997,133:109-116.
  • 8[8]Liu,K.,Olofsson,J.I.,Wahlberh,P.et al.,Distinct expression of gelatinase A[matrix metalloproteinase (MMP)-2],collagenase-3 (MMP-13),membrane type MMP 1 (MMP-14),and tissue inhibi-tor of MMPs Type 1 mediated by physiological signals during formation and regression of the rat corpus luteum,Endocrinology,1999,140:5330-5338.
  • 9[9]Duncan,W.C.,The human corpus luteum:Remodelling during luteolysis and maternal recognition of pregnancy,Rev.Reprod.,2000,5:12-17.
  • 10[10]Curry,T.E.Jr.,Osteen,K.,Cyclic changes in the matrix metalloproteinase system in the ovary and uterus,Biol.Reprod.,2001,64:1285-1296.

共引文献9

同被引文献35

  • 1杨正望,尤昭玲,冯光荣,王瑛.多囊卵巢综合征动物模型的构建及中药干预机制述评[J].湖南中医学院学报,2006,26(1):56-58. 被引量:10
  • 2孙林,魏巍,关咏梅.u-PA、u-PAR和PAI-1在睾酮联合hCG致多囊卵巢大鼠中的表达与意义[J].生殖与避孕,2006,26(10):579-583. 被引量:14
  • 3邝少松,黄小琼,饶子亮,王刚,刘广南,潘竟锵.大鼠多囊卵巢综合征动物模型血脂代谢及抗氧化作用[J].中国比较医学杂志,2007,17(9):519-522. 被引量:11
  • 4Lowe P, Kovacs G, Howlett D, et al. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust N Z J Obstet Gynaecol. 2005; 45(1):17-19.
  • 5马琳琳,吴效科.多囊卵巢综合征产科并发症及其防治[C].全国中西医结合妊娠期疾患专题学术会议论文集.2011:23-26.
  • 6Baka S, Zourla K, Kouskouni E, et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilization. In Vivo. 2010;24:293-299.
  • 7Lewandowski KC, Komorowski J, O'Callaghan C J, et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006:91:1173-1177.
  • 8Manneras L, Cajander S, Holmang A, et al. A new rat mode exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007; 148(8): 3781-3791.
  • 9Liu X, Andoh K, Mizunuma H,et al. Effects of recombinant human FSH (rhFSH), urinary purified FSH (uFSH), and hMG on small preantral follicles and tertiary follicles from normal adult and androgen-sterilized female mice. Fertil Steril. 2000; 73(2):372-380.
  • 10Yavasoglu L, Kucuk M, Coskun A,et al. Polycystic ovary syndrome and prolactinoma association. Intern Med. 2009; 48(8):611-613.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部